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Abstract
Background: Few studies have explored how utilization of outpatient services differ for HIV/HCV coinfected patients
compared to HIV or HCV monoinfected patients. The objectives of this study were to (1) compare annual outpatient
clinic visit rates between coinfected and monoinfected patients, (2) to compare utilization of HIV and HCV therapies
between coinfected and monoinfected patients, and (3) to identify factors associated with therapy utilization.
Methods: Data were from the 2005–2010 U.S. National Hospital Ambulatory Medical Care Surveys. Clinic visits with a
primary or secondary ICD-9-CM codes for HIV or HCV were included. Coinfection included visits with codes for both
HIV and HCV. Monoinfection only included codes for HIV or HCV, exclusively. Patients <15 years of age at time of visit
were excluded. Predictors of HIV and HCV therapy were determined by logistic regressions. Visits were computed using
survey weights.
Results: 3,021 visits (11,352,000 weighted visits) met study criteria for patients with HIV/HCV (8%), HIV (70%), or HCV
(22%). The HCV subgroup was older in age and had the highest proportion of females and whites as compared to
the HIV/HCV and HIV subgroups. Comorbidities varied significantly across the three subgroups (HIV/HCV, HIV, HCV):
current tobacco use (40%, 27%, 30%), depression (32%, 23%, 24%), diabetes (9%, 10%, 17%), and chronic renal failure
(<1%, 3%, 5%), (p < 0.001 for all variables). Annual visit rates were highest in those with HIV, followed by HIV/HCV, but
consistently lower in those with HCV. HIV therapy utilization increased for both HIV/HCV and HIV subgroups. HCV
therapy utilization remained low for both HIV/HCV and HCV subgroups for all years. Coinfection was an independent
predictor of HIV therapy, but not of HCV therapy.
Conclusion: There is a critical need for system-level interventions that reduce barriers to outpatient care and improve
uptake of HCV therapy for patients with HIV/HCV coinfection.
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Background
Human Immunodeficiency Virus (HIV) and hepatitis C
virus (HCV) monoinfection have been the subjects of
ample research over the past two decades; however,
HIV/HCV coinfection has only recently been documented
as a growing medical concern in the United States [1].
Combination HIV antiretroviral therapy and combination
HCV antiviral therapy have been recommended since the
late 1990s, as they each greatly reduce patient morbidity
and mortality [2,3]. While antiretroviral and antiviral
therapies are widely recommended for use in patients
with coinfection [4], these patients continue to experience
poorer health outcomes than those with monoinfection.
For instance, these individuals are at increased risk for
accelerated progression of liver disease and increased rates
of morbidity and mortality [5,6].
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If patients with coinfection do not utilize outpatient
services to the extent that patients with HIV or HCV
utilize these services, consequently, patients with coin-
fection may not be prescribed therapy to the extent that
patients with monoinfection are prescribed therapy. Few
studies to date have explored how outpatient health care
utilization patterns differ by infection status. Thus, the
extent to which patients with coinfection receive care
in the U.S. outpatient health care delivery system, as
compared to patients with monoinfection, is relatively un-
known. The U.S. health care system is based on a multi-
payer system, whereby, medical care is provided by various
independent organizations, rather than a single universal
entity. These independent organizations are largely owned
and operated by the private sector; however, other players
in the market include the U.S. government and other
non-profit organizations [7]. The multitude of health
care providers can result in various barriers to care, includ-
ing financial barriers for individuals who are uninsured or
underinsured, lack of availability of specialized profes-
sionals, and inability to reach providers [7].
The objectives of this study were to compare, between
patients with HIV/HCV coinfection and monoinfection
(HIV and HCV), (1) annual outpatient clinic visit rates,
(2) trends in yearly outpatient prescription for HCV anti-
viral therapy and HIV antiretroviral, (3) conduct multivari-
ate analysis to identify factors associated with antiretroviral
and antiviral utilization.
Methods
Data Source
The 2005–2010 U.S. National Hospital Ambulatory
Medical Care Surveys (NHAMCS) were used for this
study. The NHAMCS are nationwide probability sample
surveys that are conducted annually by the Centers for
Disease Control and Prevention (CDC). The NHAMCS
are representative of approximately 500 general and
pediatric hospital outpatient clinics, while excluding fed-
eral, military, veteran affairs, and institutional hospital
clinics. Survey data are available to the public and are a
national representation of annual clinic visit records. The
objective of the NHAMCS is to provide a population-
level estimate of the utilization of outpatient services in
the United States, therefore, some patient level data,
such as laboratory results, are not always available.
Each record consists of up to three International Classi-
fication of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) diagnosis codes and medication codes that
document up to eight medications listed at time of the
clinic visit. The outpatient clinic visits are systematically
sampled using a multi-stage process conducted by trained
field representatives (e.g., health care provider or clinic
staff) during a randomly assigned 4-week period. The vari-
ous study survey error rates typically range between 0.3%
and 0.9%; however, independently selected quality control
samples, approximately 10% of patient record forms,
are keyed and coded. Additional information about the
NHAMCS data collection process and interpretation are
available elsewhere [8].
Study design
This was a nationally representative, retrospective, cross-
sectional study. All variables were retrieved from the
NHAMCS and included patient demographics (patient
age at time of clinic visit, gender, race/ethnicity, geo-
graphic region in the United States, insurance status)
and visit characteristics (established patient, patient’s pri-
mary physician/provider, visit diagnosis, year of visit, and
providers seen). Insurance status was classified as private,
Medicare, Medicaid, self-pay, no charge, or unknown/
other. In the United States, the major insurance payers are
private insurance and government in the form of Medicare
and Medicaid [9,10]. Although both Medicare and Medic-
aid are examples of government-funded programs, they are
funded differently. Medicare is a national program de-
signed to provide medical care for older adults and is
funded by the U.S. government. Patients aged 65 or older,
with end-stage renal disease, or with certain qualifying dis-
abilities are eligible for Medicare. In contrast, Medicaid is a
state-specific program designed to provide health care to
low-income patients and is funded on the federal and state
level. Patients are eligible for this program if they meet cer-
tain criteria, however, this criteria can vary greatly based
on the individual state.
Comorbidities were based on additional clinic visit
diagnoses to include: chronic renal failure, depression,
diabetes, and current tobacco use. All clinic visits with
a primary or secondary ICD-9-CM diagnosis code for
HIV or HCV were included. The following ICD-9-CM
codes were used to identify HIV infection: 042, V08,
and 079.53 and the following codes were used to identify
HCV infection: 070.41, 070.44, 070.51, 070.54, 070.70,
and 070.71. HIV monoinfection visits excluded HCV
ICD-9-CM codes and HCV monoinfection visits ex-
cluded HIV ICD-9-CM codes. HIV/HCV coinfection
visits included those that had ICD-9-CM codes for both
HIV and HCV.
Medication drug codes were determined from the Na-
tional Center for Health Statistics (NCHS) drug database
to define HCV antiviral medications and HIV antiretro-
viral medications. HCV antiviral medications included
any of the following: ribavirin, interferon, or pegylated
interferon. HIV antiretroviral medications included any
of the following: nucleoside reverse transcriptase in-
hibitors, non-nucleoside reverse transcriptase inhibitors,
protease inhibitors, integrase inhibitors, entry inhibitors,
CCR5 antagonists, or other antiretroviral combination
products.
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Patients under the age of 15 at time of the clinic visit
were excluded. The Ethics Review Board of NCHS ap-
proves the NHAMCS on an annual basis. The University
of North Carolina Office of Human Research Ethics de-
termined that this project was not considered Human
Subjects Research according to regulatory criteria, and,
therefore, institutional review board approval was not
needed.
Data analysis
Survey weights for each observation in the survey sam-
ple were used to generate national estimates for clinic
visits. The survey weights are calculated by NCHS and
are the result of corresponding sampling fractions at
each stage in the sample design. The study weights are
adjusted for nonresponse within time of year, geograph-
ical region, and urban/rural and ownership designations,
producing an unbiased national estimate of outpatient
visit occurrences, percentages, and characteristics. In
addition, weighted estimates account for the cluster
and stratum effect of the primary sampling unit (PSU).
Weighted clinic visit estimates and disease surveillance
estimates were used to calculate annual clinic visit rates
(visits per U.S. population with diagnosed infection).
All data analyses were conducted using JMP® 8.0 and
SAS® 9.2 (SAS Institute Inc., Cary, NC). A two-tailed
alpha-level <0.05 was used to determine statistical signifi-
cance. Demographic characteristics and select comorbidi-
ties were compared across disease groups (HIV/HCV, HIV,
HCV). Survey logistic regressions were performed to deter-
mine factors associated with utilization of HIV therapy and
utilization of HCV therapy. Coinfection status was entered
into both models as an indicator variable, while adjusting
for relevant demographic covariates. SAS procedures
SURVEYFREQ, SURVEYMEANS, and SURVEYLOGISTIC
were used where appropriate.
Results
Approximately, 11,352,000 clinic visits (3,021 unweighted
observations) met study criteria for patients with HIV/
HCV coinfection (8%), HIV monoinfection (70%), or HCV
monoinfection (22%) between 2005 and 2010. A compari-
son of demographics, select comorbidities, and outpatient
visit characteristics by infection group is presented in
Table 1. In general, the HCV group was older in age and
had the highest proportion of females and whites as com-
pared to the HIV/HCV and HIV groups. Clinic visits pre-
dominantly occurred in the southern United States and the
most common form of insurance coverage listed across all
groups was Medicaid, followed by Medicare. The following
comorbidities varied significantly across the three groups
(HIV/HCV, HIV, HCV): current tobacco use (40%, 27%,
30%), depression (32%, 23%, 24%), diabetes (9%, 10%, 17%),
and chronic renal failure (<1%, 3%, 5%), (p < 0.001 for all
variables). The majority of patients had previously estab-
lished care at the clinic that they visited. Physicians often
provided care at these visits (approximately 80% for all
three groups). By comparison, nurse practitioners and
physician assistants provided care less often. In contrast,
nurses provided care at approximately two-thirds of visits
for the HIV/HCV and HIV groups, but only provided care
at half of visits for the HCV group (p < 0.001). It was more
common for those with HIV/HCV to visit with their pri-
mary care provider/physician, as compared to those with
either HIV monoinfection or HCV monoinfection.
For all study years, annual visit rates were highest in
those with HIV, followed by HIV/HCV (Figure 1). An-
nual visit rates were consistently lower in those with
HCV. Documentation of HCV antiviral therapy utilization
remained low for both HIV/HCV and HCV groups for all
years (Figure 2). Results from the logistic regression to
identify predictors of HCV therapy are presented in
Table 2. Presence of depression as a comorbidity was asso-
ciated with decreased odds of HCV therapy (adjusted odds
ratio [95% CI]; 0.265 [0.131 - 0.536]). HIV/HCV coinfec-
tion (compared to HCV monoinfection) was not associated
with HCV therapy. HIV antiretroviral therapy utilization
increased for both HIV/HCV and HIV groups; the increase
was more pronounced in the HIV/HCV group (Figure 3).
Per regression analysis in Table 3, HIV/HCV coinfection
(compared to having HIV alone) was associated with in-
creased odds of HIV therapy (p < 0.01 in all years). Nega-
tive predictors of HIV therapy included African-American
race/ethnicity (p = 0.045) and no charge for the clinic visit
(p = 0.044).
Discussion
This is one of the first studies to compare outpatient
utilization patterns for HIV/HCV coinfection, HIV mono-
infection and HCV monoinfection on a national perspec-
tive. One advantage to the observational nature of the
study design is the generalizability of the findings. The
study evaluated patterns of care in the outpatient setting
and are therefore, more reflective of actual clinical practice
as compared to results from studies that are conducted in
a controlled setting. This study reveals that there are differ-
ences in utilization of outpatient services based on infec-
tion status (coinfection vs. monoinfection). Differences in
demographic characteristics across the three groups noted
in this study are consistent with prior studies. Patients with
HIV tended to be younger in age [11], of male gender
[11,12], and of African-American race [11,12], as compared
to patients with HCV.
An unexpected finding was the variation of clinic visit
rates by infection type; there were more visits for pa-
tients with HIV than for patients with HCV, including
those with coinfection. National surveillance data estimate
that approximately 5.2 million persons in the United States
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Table 1 Comparison of demographics, select comorbidities, and outpatient visit characteristics in patients with HIV/
HCV, HIV, and HCV
Characteristic HIV/HCV coinfection HIV monoinfection HCV monoinfection P-value
No. of Unweighted Observations 200 1992 829
No. of Visits in 1000s (95% CI) 859 (422–1296) 7,926 (4,772–11081) 2,567 (1658–3476) <0.001
Proportion of Study Visits 8% 70% 22%
Patient demographics - - -
Age (years), mean (95% CI) 46.4 (43.1–49.7) 42.9 (41.6–44.2) 50.4 (49.0–51.9) <0.001
Gender - - - <0.001
Male (%) 64 68 59 -
Female (%) 36 32 41 -
Race/ethnicity (%) - - - <0.001
White 31 25 56 -
African-American 49 50 29 -
Hispanic 18 23 11 -
Other 1 2 4 -
Geographic region (%) - - - <0.001
Northeast 30 26 28 -
Midwest 11 18 9 -
West 7 12 10 -
South 52 43 53 -
Insurance status (%) - - - 0.051
Private 4 16 23 -
Medicare 20 16 14 -
Medicaid 45 43 31 -
Other/unknown 11 11 10 -
Self-pay 3 4 8 -
No Charge 17 9 14 -
Comorbidities - - - -
Chronic Renal Failure (%) <1 3 5 <0.001
Depression (%) 32 23 24 <0.001
Diabetes (%) 9 10 17 <0.001
Current Tobacco Use (%) - - - <0.001
Yes 40 27 30 -
No 28 28 38 -
Unknown 32 45 32 -
Visit characteristics - - - -
Established Patient (%) 94 93 83 <0.001
Patient’s Primary Care Physician/Provider (%) - - - <0.001
Yes 48 36 35 -
No 49 58 60 -
Unknown 3 6 5 -
Providers Seen (%) - - - -
Physician 81 79 80 0.5
RN/LPN 63 64 54 <0.001
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are chronically infected with HCV, whereas approximately
1.1 million persons in the United States are infected with
HIV [13,14]. The epidemiologic burden of HCV is greater
than that of HIV, but utilization of outpatient care was
relatively low for this patient population. In addition, it is
estimated that one quarter of individuals living with HIV
are coinfected with HCV [15]. Given that HIV requires
lifelong management, and therefore necessitates routine
outpatient care, one would expect that patients with HIV/
HCV visit the clinic at least to the same extent as patients
with only HIV. From a public health standpoint, this im-
plies that coinfected individuals are not entering into care
at the same rate as HIV monoinfected individuals. Low
utilization of outpatient services precludes coinfected pa-
tients from receiving timely antiviral or antiretroviral ther-
apies, leading to increased utilization of acute care services
such as emergency department visits and hospital admis-
sions [16]. These findings highlight the need to reduce
entry to care barriers for this patient population.
Outpatient prescriptions for antiviral therapy was quite
low across both groups with HCV. However, utilization
was slightly lower for those with coinfection compared
to those with monoinfection (7% vs. 10%, respectively).
Uptake of HCV therapy has historically been low. Two
separate studies by Cheung et al. [17] and Tsui et al.
[18] sought to evaluate antiviral treatment rates for out-
patient visits in patients with HCV, using national survey
data. Both investigators reported that fewer than 10% of all
HCV-related patient visits documented antiviral therapy.
Data from these two studies were only through 2006,
whereas data from the present investigation are through
2010. Nevertheless, the findings still persist; antiviral treat-
ment rates in the United States have remained unchanged
over the past several years. More efforts are needed to im-
prove HCV treatment utilization rates.
The studies by Cheung et al. and Tsui et al. did not
make a distinction for patients with monoinfection vs.
patients with coinfection. Patients that are dually infected
tend to experience accelerated progression of end-stage
liver disease leading to increased risk of morbidity and
mortality [5,6,19-21]. This distinction is important given
their unique, clinical needs. Butt et al. conducted an inves-
tigation to compare treatment rates in patients with mono-
infection vs. patients with coinfection [12]. Eligible patients
were recruited and referred for HCV care to infectious
diseases/HIV and hepatology clinics. Given that these pa-
tients were prospectively referred for HCV care to spe-
cialty clinics, it is not surprising that the overall treatment
rate was relatively high at 50%. Nevertheless, the inves-
tigators determined that HCV treatment rates were lower
in patients with coinfection compared to patients with
monoinfection (32% vs. 62%; p < 0.001). Coinfection status
was also independently associated with a decreased likeli-
hood of HCV treatment, despite controlling for factors in
Table 1 Comparison of demographics, select comorbidities, and outpatient visit characteristics in patients with HIV/
HCV, HIV, and HCV (Continued)
Nurse practitioner/midwife 14 13 14 0.2
Physician assistant 4 4 4 0.6
Other 23 25 20 <0.001
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Figure 1 Trends in annual outpatient clinic visit rates for patients with HIV/HCV, HIV, or HCV infection.
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multivariate analysis (adjusted OR 0.33, 95% CI 0.21-0.53).
Lower treatment rates for patients with HIV/HCV receiv-
ing care in specialized settings have been reported else-
where. Scott et al. conducted a retrospective evaluation of
HCV therapy in a cohort of HIV patients receiving pri-
mary care at a HIV specialty clinic [22]. Only 16% of
clinic patients ever received antiviral therapy. Similar pro-
portions were noted in longitudinal data from the HIV
Outpatient Study (HOPS); only 20% of 507 patients with
confirmed coinfection initiated HCV treatment during
the period of observation [6]. While an increasing pro-
portion of HOPS participants were treated over the 3-year
baseline periods in 1999–2001 (19%), 2002–2004 (21%)
and 2005–2007 (28%), this overall rise was not statistically
significant (p = 0.3). However, time for treatment initiation
following confirmed HCV diagnosis decreased significantly
(p < 0.001). Collectively, these findings underscore the on-
going issue of low HCV treatment uptake, particularly in
patients with coinfection.
According to guideline recommendations, the primary
goal of HCV therapy is to achieve a sustained virologic
response (SVR) six months post treatment [23,24]. Such
a response is effectively consistent with HCV cure for
patients and greatly reduces progression to end-stage
liver disease, hepatocellular carcinoma (HCC), and death
[25–27]. To achieve this goal, therapy should be consid-
ered for all patients with chronic HCV. Pre-treatment
assessments should be performed as certain conditions
may preclude patients from receiving therapy. For in-
stance, treatment is not recommended for patients with
decompensated liver disease, severe uncontrolled psychi-
atric illness, and current alcohol and/or substance abuse
[23]. Historically, antiviral treatment rates have been low
due to concerns of side effects and/or adverse events asso-
ciated with HCV standard of care with pegylated interferon
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Figure 2 Clinic visits that documented HCV antiviral therapy prescription (HIV/HCV vs. HCV).
Table 2 Multivariate regression analysis of factors
associated with HCV antiviral therapy
Adjusted OR (95% CI) P-value
Age 0.969 (0.934, 1.005) 0.0892
Gender
Female 1 -
Male 0.805 (0.346, 1.872) 0.6138
Race
White, non Hispanic 1 -
African-American, non Hispanic 1.019 (0.399, 2.603) 0.3692
Hispanic 1.882 (0.671, 5.28) 0.3924
Other 1.93 (0.515, 7.237) 0.4715
Region
Northeast 1 -
Midwest 1.734 (0.368, 8.172) 0.6205
West 0.920 (0.269, 3.144) 0.438
South 1.857 (0.686, 5.026) 0.277
Insurance
Private Insurance 1 -
Medicare 3.373 (0.665, 17.097) 0.1527
Medicaid 2.257 (0.481, 10.592) 0.5098
Other/unknown 1.300 (0.204, 8.276) 0.4562
Self-pay 2.440 (0.559, 10.644) 0.4657
No Charge 1.903 (0.494, 7.335) 0.9823
Depression 0.265 (0.131, 0.536) 0.0002
HIV/HCV Coinfection vs. HCV
Monoinfection
2005-2006 (year of visit) 0.5145 (0.148, 1.789) 0.296
2007-2008 (year of visit) 0.3082 (0.014, 6.943) 0.4589
2009-2010 (year of visit) 0.3293 (0.039, 2.786) 0.3079
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and ribavirin (pegIFN + RBV). Reported adverse events
often include hemolytic anemia associated with ribavirin
use and influenza-like symptoms and neuropsychiatric ef-
fects associated with interferon use [23]. Fortunately, im-
proved direct-acting antiviral (DAA) agents are associated
with improved SVR rates and are now guideline-endorsed
for use in combination with pegIFN + RBV [24]. The possi-
bility of IFN-free regimens is also on the horizon [28]. For
current clinical practice, particularly for those with coin-
fection, pegIFN + RBV are still a key component of the
regimen. It has been projected that the addition of DAA
agents to pegIFN + RBV will actually increase regimen
complexity over the next few years as data emerge from
clinical trials [20,29]. Other treatment considerations still
include the concern for increased pill burden and the
potential for drug-drug interactions with HCV medications
and concomitant administration of antiretroviral therapy.
Efforts are needed to improve HCV treatment utilization
rates, particular in patients with coinfection.
Outpatient antiretroviral therapy increased in both
groups with HIV. The goals of antiretroviral therapy in-
clude viral suppression, transmission prevention, and the
restoration and preservation of immune function [30].
Since the eradication of the virus is not achieved by avail-
able antiretroviral medications, duration of HIV therapy
is considered to be a lifelong commitment. It is expected
that HIV therapy utilization was greater than HCV ther-
apy utilization at the time of clinic visit. Other studies
have reported high and/or rising use of HIV therapy,
in both coinfection and monoinfection [6,11,31]. With
regards to those with HIV/HCV, the majority (87%) of pa-
tients in the aforementioned HOPS study had some form
of prior exposure to antiretroviral therapy [6]. High use is
consistent with national treatment guidelines which now
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Figure 3 Clinic visits that documented HIV antiretroviral therapy prescription (HIV/HCV vs. HIV).
Table 3 Multivariate regression analysis of factors
associated with HIV antiretroviral therapy
Adjusted OR (95% CI) P-value
Age 1.012 (0.998, 1.025) 0.1024
Gender
Female 1 -
Male 1.306 (0.823, 2.073) 0.2571
Race
White, non Hispanic 1 -
African-American, non Hispanic 0.682 (0.500, 0.932) 0.4559
Hispanic 0.795 (0.486, 1.301) 0.9695
Other 0.759 (0.211, 2.725) 0.9097
Region
Northeast 1 -
Midwest 1.271 (0.545, 2.966) 0.211
West 0.442 (0.137, 1.421) 0.098
South 1.148 (0.589, 2.238) 0.2706
Insurance
Private Insurance 1 -
Medicare 0.87 (0.588, 1.286) 0.1827
Medicaid 0.547 (0.298, 1.005) 0.0526
Unknown/other 0.602 (0.324, 1.119) 0.0531
Self-pay 0.521 (0.216, 1.258) 0.1352
No Charge 0.629 (0.398, 0.996) 0.0437
HIV/HCV Coinfection vs. HIV
Monoinfection
2005-2006 (year of visit) 2.533 (1.618, 3.965) <.0001
2007-2008 (year of visit) 7.464 (1.9, 29.317) 0.004
2009-2010 (year of visit) 2.888 (1.364, 6.117) 0.0056
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recommend antiretroviral therapy for all HIV-infected in-
dividuals, regardless of CD4 cell count, to reduce the risk
of disease progression and for the prevention of the HIV
transmission [30]. Fortunately, the advent of newer anti-
retroviral medications has lessened the concern for regi-
men complexity, drug-drug interactions, and pill burden.
In the present study, the rise in antiretroviral coverage was
more pronounced for those with coinfection, with the
proportion rising from 54% in 2005–2006 to 93% in
2009–2010. This finding implies that HIV treatment is im-
proving for this patient population. However, this only ap-
plies to patients that are in care. As described earlier, it
was expected that the coinfection clinic visit rate would
mirror that of the HIV monoinfection rate, but in fact,
the rate was lower. Continued efforts are needed to en-
gage patients diagnosed with HIV/HCV coinfection into
outpatient care.
One of our findings was that African-American race/
ethnicity was associated with lower odds of HIV anti-
retroviral therapy. Racial disparities in access to regular
HIV care still persist; African-Americans have been
shown to have sub-optimal engagement in the HIV con-
tinuum of care, particularly African-American males and
African-American youth [32]. Gaston et al. recently con-
ducted a systematic review to understand factors that
influence engagement and adherence to HIV medical
care among African-Americans [33]. A review of the 16
studies revealed that lack of social support, perceived
discrimination and racism, and conspiracy beliefs about
HIV and related treatments were barriers to HIV care,
whereas, good quality relationships with health care pro-
viders facilitated adherence to HIV-related care [33].
Engagement in outpatient care is key for the manage-
ment of both HIV and HCV. Despite recent and emer-
ging advances in treatment, barriers to care persist,
particularly for HCV care. The most common barriers
are at the systems level (e.g., limited infrastructure for
assessment and treatment, accessing care, high treat-
ment costs), provider level (e.g., perceptions of poor pa-
tient adherence, concerns for active drug abusers, lack of
experience treating patients), and at the patient level (e.g.,
lack of knowledge, misconceptions, level of motivation)
[20,34]. Potential strategies to improve engagement in care
include routine HCV testing and linking patients to care
immediately following diagnosis. Furthermore, HCV care
services can be expanded to other primary care services,
which can be accomplished through cross-specialty pro-
vider education and training and patient pretreatment
education [35]. Future research should delve further into
outpatient utilization patterns to evaluate differences in
contextual factors, adherence to prescribed medications,
and patient-perceived barriers to care. A comprehensive
approach that addresses these barriers can help to improve
entry to outpatient care.
This study is subject to some limitations. The multi-
variate analysis conducted within this study should be
interrupted carefully. The NHAMCS are designed to
provide population-level estimates. Certain patient-levels
factors that can be helpful in determining treatment ini-
tiation were unavailable. As such, multivariate analyses
in this study did not adjust for HCV genotype, viral load,
CD4 cell count, and patients’ medical history. Add-
itionally, despite spanning 13 years, the study was not
longitudinal and could not assess which patients were
continuing with care over time. Findings represent only a
snapshot in time and it is difficult to infer future trends.
The NHAMCS data are presented as visit-level data ra-
ther than patient-level data; it is possible that the analysis
captures patients that are sampled multiple times. How-
ever, only a patient returning to the clinic within the
four-week reporting interval would potentially be sam-
pled more than once. The NHAMCS survey instrument
has a restriction on the maximum number of medica-
tions; no more than eight medications can be docu-
mented at time of visit. It is not uncommon for patients
with HIV or HCV to use multiple medications. There-
fore, we did not assess regimen appropriateness; rather,
we evaluated documentation of any antiviral or antiretro-
viral medication. Up until 2005, medications were coded
based on a 5-digit drug code. Starting in 2006, medica-
tions were coded based on a 6-digit code (in addition to
the 5 digit code). We cross-referenced all codes to ensure
accuracy in identifying medications.
Data regarding physician specialty (e.g., hepatologist,
infectious diseases specialist) and detailed patient histories
(e.g., past medication histories, prior treatment response,
objective laboratory data) were not available in these sur-
veys. Rather, we were able to assess patients that were vis-
iting their primary care physician/provider as well as other
types of health care professionals that provided care dur-
ing the visit. Other providers in the U.S., such as nurse
practitioners and physician assistants, have prescriptive
authority when practicing under the direction of a super-
vising physician. Including the various types of providers
seen is an indicator for a multidisciplinary approach to
care for these patients. Moreover, we found that the ma-
jority of all patients had previously established care at the
clinics that they visited, which is indicative of continued
engagement in care at that facility.
Conclusions
These data provide national, population-level estimates
for health care utilization trends in patients with HIV/
HCV, HIV, or HCV. Patients with coinfection have dif-
ferent medical needs compared to those with HIV or
HCV alone. Nevertheless, prescription of HCV therapy
remains low in the outpatient setting. While HIV ther-
apy utilization was greater in patients with HIV/HCV
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than those with HIV, consistently lower clinic visit rates
for the latter group reveal a disparity in the use of out-
patient services. There is a critical need for system-level
interventions that reduce barriers to care. Such efforts
can improve treatment-related outcomes for this patient
population. Future studies should investigate how health
care utilization and HCV-related outcomes differ for pa-
tients with HIV/HCV compared to patients with HCV
monoinfection, specifically in the context of DAA-based
antiviral therapy.
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